MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00266344

Enrollment

520

Registered

2005-12-16

Start date

2005-11-30

Completion date

2006-10-31

Last updated

2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Brief summary

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Interventions

DRUGMK0928, gaboxadol / Duration of Treatment 3 Weeks

DRUGPlacebo / Duration of Treatment 3 Weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Patients with a diagnosis of primary insomnia

Exclusion criteria

* Patients with an active psychiatric disorder other than primary insomnia

Design outcomes

Primary

Measure	Time frame
Patient-reported total sleep time.	—

Secondary

Measure	Time frame
Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026